Melanoma Clinical Trials in Dallas

Showing 101-120 of 129 trials

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

NCT00121680

The purpose of this study is to study the safety of E7080 administered to patients with solid tumors or lymphomas. Please note: this study is now recruiting patients with advanced and/or metastatic melanoma only. In the current phase of this study, To determine the MTD and the pharmacokinetic profile of E7080 when given as continuous daily (qd) dosing in combination with temozolomide.

Metastatic Melanoma

Eisai Inc.115 participantsStarted Jul 2005

Dallas, Texas, United States • Houston, Texas, United States

TERMINATEDPHASE2< 1 mile

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

NCT01709162

The purpose of the study is to determine whether additional doses of ipilimumab have a positive effect on survival in the treatment of advanced melanoma that has progressed after successful initial treatment with ipilimumab.

Melanoma

Bristol-Myers Squibb31 participantsStarted Mar 2013

Birmingham, Alabama, United States • Aurora, Colorado, United States • Indianapolis, Indiana, United States +14 more locations

COMPLETEDPHASE2< 1 mile

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

NCT00533702

The primary objective of this study is to determine the progression-free survival (PFS) of participants with previously untreated metastatic malignant melanoma when treated with IMC-1121B (ramucirumab) alone or in combination with dacarbazine.

Metastatic Malignant Melanoma

Eli Lilly and Company106 participantsStarted Nov 2007

Decatur, Alabama, United States • Scottsdale, Arizona, United States • Scottsdale, Arizona, United States +14 more locations

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Melanoma Trials in Other Cities

Vaccine Therapy in Treating Patients With Malignant Melanoma

Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients

S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy

Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma

S9804: Vinorelbine in Treating Patients With Stage IV Melanoma

Phase II, 2nd Line Melanoma - RAND Monotherapy

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

Study of CP-675,206 in Refractory Melanoma

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

SciBase International Melanoma Pivotal Study

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis

Other Conditions in Dallas